News & Updates
Filter by Specialty:
Does fMRI neurofeedback improve symptoms, cognition in children with ADHD?
Nonpharmacological treatment with functional magnetic resonance imaging neurofeedback (fMRI-NF) of the right inferior frontal cortex (rIFC) does not seem effective in improving clinical symptoms or cognition in boys with attention deficit hyperactivity disorder (ADHD), reports a recent study.
Does fMRI neurofeedback improve symptoms, cognition in children with ADHD?
13 Dec 2022
Do supplements measure up to statins for lipid-lowering?
In individuals with increased 10-year risk for ASCVD*, rosuvastatin 5 mg significantly reduced LDL-C** and other lipid and inflammatory biomarkers compared with placebo and six widely used heart health supplements, results from the SPORT*** trial have shown.
Do supplements measure up to statins for lipid-lowering?
13 Dec 2022
Prostate cancer genomic study shows disparity between Chinese and Caucasians with castration-sensitive disease
A large genomic study involving 1,016 Chinese patients with prostate cancer has revealed important differences in castration-sensitive disease between Chinese and Caucasian patients, but the mutation profile of metastatic castration-resistant prostate cancer (mCRPC) is similar between the populations.
Prostate cancer genomic study shows disparity between Chinese and Caucasians with castration-sensitive disease
13 Dec 2022
Low-dose polypill: Another step forward in hypertension management?
A polypill comprising ultra-low doses of four antihypertensive drugs shows promise in reducing blood pressure (BP) levels compared with standard monotherapy, according to a small study presented at AHA 2022.
Low-dose polypill: Another step forward in hypertension management?
12 Dec 2022
Asians with MET exon 14 skipping NSCLC achieve durable response with tepotinib
The MET inhibitor tepotinib demonstrates clinically meaningful antitumour activity, with durable efficacy and manageable safety profile in Asian nonsmall cell lung cancer (NSCLC) patients with MET mutations associated with exon 14 skipping, as shown in the subset analysis of the single-arm, phase II VISION study.